Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 929,600 shares, an increase of 562.1% from the February 28th total of 140,400 shares. Based on an average daily volume of 14,530,000 shares, the short-interest ratio is presently 0.1 days. Approximately 8.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a report on Tuesday, November 26th. Finally, D. Boral Capital started coverage on Plus Therapeutics in a report on Monday, March 17th. They set a “buy” rating and a $9.00 target price for the company.

Plus Therapeutics Stock Performance

Shares of PSTV traded up $0.04 during mid-day trading on Wednesday, reaching $1.47. 6,078,201 shares of the company’s stock traded hands, compared to its average volume of 3,853,771. The business’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.23. The stock has a market capitalization of $8.67 million, a P/E ratio of -0.58 and a beta of 0.73. Plus Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.67.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.